Clevidipine Structure And Formula (Cleviprex Figure 1)
Cleviprex Emulsion
Product Images NDC 18124-011
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Cleviprex (NDC 18124-011). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Fresenius Kabi Austria Gmbh, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Package Label (Principal Display Panel)
Package Label (Principal Display Panel)
Package Label (Principal Display Panel)
This appears to be a label of a medication named Cleviprex. It includes information about the concentration of the medication, the NDC code, and the amount of single-use vials provided. Not enough information is provided to determine the usage and application instructions for this medication.*
Package Label (Principal Display Panel)
(clevidipine) injectable emulsion with a concentration of 125 mg per 250 mL, equivalent to 0.5 mg/m. The remaining text is not readable and appears to be a mix of numbers, letters, and symbols.*
Package Label (Principal Display Panel)
This is a medication label for Clevidipine Injectable Emulsion. It contains information on dosage and storage instructions. The medication is contraindicated for patients with impaired liver or kidney function and severe aortic stenosis. It must be stored at room temperature and not be frozen. The label warns against contamination and advises on proper disposal after two months of use. Details of proper handling and administration are included. There is also a warning against using the medication beyond two months after opening the container.*
Package Label (Principal Display Panel)
This is a description of a drug named Cleviprex, which is an injectable emulsion of 125 mg / 250 mL (0.5 mg/mL). It comes in single-use vials and is for intravenous use only. This text also provides warnings for storage and handling of the drug.*
Figure 1. Mean Change In Systolic Blood Pressure (mmhg) During 30-minute Infusion, Escape-1 (preoperative) (Cleviprex Figure 2)
This is a graph that shows the mean change in systolic blood pressure (in mmHg) from baseline, over time (in minutes). The graph compares the effects of Clevidipine versus a placebo. No further information can be obtained from the given text.*
Figure 2. Mean Change In Systolic Blood Pressure (mmhg) During 30-minute Infusion, Escape-2 (postoperative) (Cleviprex Figure 3)
The text describes a chart or graph displaying the mean change in systolic blood pressure (in mmHg) from baseline over 30 minutes. The chart also includes data on the number of participants who dropped out during the 30-minute infusion. The x-axis shows time in minutes, with data points at 10, 15, 20, 25, and 30 minutes.*
Figure 3. Mean Change In Heart Rate (bpm) During 30-minute Infusion, Escape-1 (preoperative) (Cleviprex Figure 4)
Figure 4. Mean Change In Heart Rate (bpm) During 30-minute Infusion, Escape-2 (postoperative) (Cleviprex Figure 5)
Clevidipine is a medication indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable. The text seems to be incomplete and does not provide any further descriptive information.*
Figure 5. Mean Percent Change In Sbp (%) During The First 30 Minutes Of Infusion, Velocity (severe Hypertension) (Cleviprex Figure 6)
Package Label (Principal Display Panel)
Package Label (Principal Display Panel)
This appears to be a mixture of product names, dosage information, and administration instructions for injectable emulsions. The products mentioned are Cleviprex and Clvidipine, both of which are 25mg/50 mL (0.5 mg/mi) injectable emulsions. The text mentions a single-use vial and discarding any unused portion, as well as instructions for administration. Without additional context on the purpose and use of these products, it is difficult to provide a more specific description.*
Package Label (Principal Display Panel)
Description: This appears to be a medication prescription label containing information about two different injectable emulsions with the brand names Viaks and Romy. Each emulsion contains 25mg or 0.5 mg of an active ingredient in a 50mL solution and is intended for single-use, intravenous administration.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
